PT-141 vs KPV

Side-by-side comparison of PT-141, KPV — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute PT-141 PT-141 (Bremelanotide) Recovery KPV KPV (Lys-Pro-Val) — Alpha-MSH Tripeptide Recovery
Basics
Molecular type Melanocortin Receptor AgonistAlpha-MSH C-terminal Tripeptide
Amino acids 73
Molecular weight 1,025.2 Da355.4 Da
Half-life ~2.7 hoursShort (hours)
Route(s) Subcutaneous auto-injectorSubcutaneous, Oral (GI conditions), Topical
Mechanism & Research
Primary mechanism PT-141 activates melanocortin receptors in the central nervous system — particularly MC3R and MC4R in the hypothalamus and limbic regions. Unlike PDE5 inhibitors (sildenafil, tadalafil) which work peripherally through va… KPV binds melanocortin receptors (MC1R and MC3R) expressed on immune cells, epithelial cells, and neurons. Receptor activation suppresses NF-κB-mediated pro-inflammatory cytokine production (TNF-α, IL-6, IL-8) and drives…
Research status FDA Approved (Vyleesi) Research Compound
Evidence summary PT-141 (Bremelanotide) was FDA-approved in 2019 based on two Phase 3 trials in premenopausal women with HSDD. Research in men demonstrates pro-erectile effects and is ongoing. KPV has robust preclinical data for inflammatory bowel conditions (Crohn's disease, ulcerative colitis models) and wound healing. Oral nanoparticle formulations have been developed to improve colonic delivery.
Protocol & Dosing
Typical dose 1.75 mg (FDA-approved dose)500 mcg–2 mg/day (SC); variable oral dosing
Frequency As needed (max 1x per 24 hours)Once or twice daily
Duration As needed4–8 weeks
Timing 45 minutes before anticipated sexual activityAny time; pre-meals for GI applications
Safety
Common side effects
  • Nausea (40%)
  • Flushing (20%)
  • Headache (11%)
  • Injection site bruising
  • Injection site redness (SC)
  • Mild skin darkening (possible — MC1R activity)
  • Headache (rare)
Contraindications
  • Uncontrolled hypertension
  • Known cardiovascular disease
  • Use of PDE5 inhibitors (synergistic BP drop)
  • Known melanocortin sensitivity
  • Pregnancy (insufficient data)
  • Active melanoma (MC1R concern)
Anti-doping Not Prohibited Not Prohibited
Deeper reading
Related peptides KPV, Semax BPC-157, LL-37, TB-500
Full profile Read full PT-141 profile → Read full KPV profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.